Non-Hodgkin Lymphoma — Trials

Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,168
Recruiting: 1,127
Ph III recruiting: 115
Growth YoY: +5.7%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%
Trials / 1,000 deaths: 108.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,290)

clinicaltrialsPublishedShowing 251–300 of 3,875 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01297764	A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma(QUAD)	active not recruiting	Phase 1 / Phase 2	17	Hackensack Meridian HealthOTHER	1	Aug 24, 2026	clinicaltrials
NCT03410875	A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia	active not recruiting	Phase 2	30	Memorial Sloan Kettering Cancer CenterOTHER